Predictive Value of Glycemic Parameters Measured With the FSL Pro iQ During ACS

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 850 participants.

Also called NCT06014112

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose prevention
Phase
Not applicable
Enrolled
  • 850 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06014112
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
France (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06014112. Allocation not applicable; no masking; primary purpose prevention. Start 2023-11-06 (actual); primary completion 2028-05-06 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Predictive Value of Glycemic Parameters Measured With the FSL Pro iQ During ACS
Acronym
FREESCA
Condition
Acute Coronary Syndrome
Condition
Continuous Glucose Measurement
Condition
Glycemic Variability
Condition
Cardiovascular Event
Intervention (Device)
Freestyle Libre Pro iQ
Lead sponsor
University Hospital, Montpellier (class: other)

Record details

Record id
cardio:ct-nct06014112
Content hash
86ee420fc740763494a7572583f4494f895830a26a1391a6da60d45b56429e5a